Holen Sie sich die Stockscreener-App
48.59
3.71%
-1.87
Handel nachbörslich:
48.25
-0.34
-0.70%
Schlusskurs vom Vortag:
$50.46
Offen:
$50.07
24-Stunden-Volumen:
908.09K
Relative Volume:
0.87
Marktkapitalisierung:
$3.44B
Einnahmen:
-
Nettoeinkommen (Verlust:
$-141.43M
KGV:
-19.77
EPS:
-2.4581
Netto-Cashflow:
$-226.41M
1W Leistung:
-9.60%
1M Leistung:
-26.99%
6M Leistung:
+106.06%
1J Leistung:
+122.18%
1-Tages-Spanne:
$47.71
$50.40
1-Wochen-Bereich:
$47.71
$61.20
52-Wochen-Spanne:
$13.22
$94.90
Structure Therapeutics Inc Adr Stock (GPCR) Company Profile
Firmenname
Structure Therapeutics Inc Adr
Sektor
Branche
Telefon
(650) 457-1978
Adresse
601 GATEWAY BLVD SUITE 900, SOUTH SAN FRANCISCO
Compare GPCR vs VRTX, REGN, ALNY, ARGX, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
GPCR
Structure Therapeutics Inc Adr
|
48.59 | 3.44B | 0 | -141.43M | -226.41M | -2.4581 |
VRTX
Vertex Pharmaceuticals Inc
|
454.00 | 115.33B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
732.87 | 77.48B | 14.34B | 4.50B | 3.77B | 41.56 |
ALNY
Alnylam Pharmaceuticals Inc
|
312.17 | 41.40B | 3.71B | 313.75M | 465.38M | 2.2571 |
ARGX
Argen X Se Adr
|
663.93 | 41.09B | 4.16B | 1.29B | 734.26M | 19.58 |
ONC
Beone Medicines Ltd Adr
|
275.28 | 30.56B | 5.36B | 287.73M | 924.18M | 2.5229 |
Structure Therapeutics Inc Adr Stock (GPCR) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-05-02 | Eingeleitet | Citigroup | Buy |
| 2025-02-28 | Eingeleitet | William Blair | Outperform |
| 2025-01-08 | Eingeleitet | Stifel | Buy |
| 2024-12-04 | Eingeleitet | H.C. Wainwright | Buy |
| 2024-09-23 | Eingeleitet | Morgan Stanley | Overweight |
| 2024-05-21 | Eingeleitet | JP Morgan | Overweight |
| 2024-04-09 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2023-10-19 | Eingeleitet | JMP Securities | Mkt Outperform |
| 2023-07-27 | Eingeleitet | Piper Sandler | Overweight |
| 2023-05-25 | Fortgesetzt | Jefferies | Buy |
| 2023-02-28 | Eingeleitet | BMO Capital Markets | Outperform |
| 2023-02-28 | Eingeleitet | Guggenheim | Buy |
| 2023-02-28 | Eingeleitet | Jefferies | Buy |
| 2023-02-28 | Eingeleitet | SVB Securities | Outperform |
Alle ansehen
Structure Therapeutics Inc Adr Aktie (GPCR) Neueste Nachrichten
Structure Therapeutics Slides 28% This Year as $6 Million Stake Emerges - AOL.com
B Group Acquires 4.62% Portfolio Stake in Structure Therapeutics | 2025 InvestmentNews and Statistics - IndexBox
LifeSci Capital Keeps Their Buy Rating on Structure Therapeutics, Inc. Sponsored ADR (GPCR) - The Globe and Mail
Did Positive Phase 2 Aleniglipron Data Just Shift Structure Therapeutics' (GPCR) Investment Narrative? - Sahm
How (GPCR) Movements Inform Risk Allocation Models - Stock Traders Daily
Structure Therapeutics (NASDAQ:GPCR) Shares Down 7.5%Should You Sell? - MarketBeat
Why Structure Therapeutics Shares Are Tumbling Today - TipRanks
Analysts Offer Insights on Healthcare Companies: Neurosense Therapeutics Ltd. (NRSN), Structure Therapeutics, Inc. Sponsored ADR (GPCR) and Lifecore Biomedical (LFCR) - The Globe and Mail
What is HC Wainwright's Forecast for GPCR FY2027 Earnings? - MarketBeat
Analysts Offer Insights on Healthcare Companies: Merit Medical Systems (MMSI), Voyager Therapeutics (VYGR) and Structure Therapeutics, Inc. Sponsored ADR (GPCR) - The Globe and Mail
Wall Street Analysts Are Bullish on Top Healthcare Picks - The Globe and Mail
Structure Therapeutics Posts 15%+ Weight Loss in ACCESS II for Oral GLP-1 Aleniglipron, Eyes Phase III - MarketBeat
Buy Rating on GPCR Driven by Competitive Aleniglipron Phase 2b Efficacy and Clear Path to Phase 3 in Obesity - TipRanks
Analysts Are Bullish on Top Healthcare Stocks: HeartBeam (BEAT), Structure Therapeutics, Inc. Sponsored ADR (GPCR) - The Globe and Mail
Structure Therapeutics Oral GLP-1 Obesity Drug Achieves ‘Injectable-Like Efficacy’ in Phase 2 Test - MedCity News
Structure Therapeutics’ Stock Climbing Amid 44-Week Trial Data Buzz - StocksToTrade
William Blair reiterates Structure Therapeutics stock rating on trial data By Investing.com - Investing.com Canada
Structure Therapeutics (NASDAQ:GPCR) Sees Strong Trading VolumeStill a Buy? - MarketBeat
Structure Therapeutics (NASDAQ:GPCR) Given New $100.00 Price Target at HC Wainwright - MarketBeat
Structure Therapeutics ADR receives Investment Bank Analyst Rating Update By Investing.com - Investing.com Canada
Structure Therapeutics (GPCR) Stock Surges 10% as GLP-1 Pill Outperforms Lilly and Novo - CoinCentral
Leerink reiterates Outperform on Structure Therapeutics stock - Investing.com
Structure Therapeutics Reports Strong Phase 2 Obesity Drug Results - TipRanks
Structure Therapeutics Inc Reports Positive Topline Data From Phase 2 ACCESS II Trial With Once-Daily Oral Small Molecule GLP-1 Receptor Agonist Aleniglipron - marketscreener.com
Structure Therapeutics (NASDAQ: GPCR) shows 16% weight loss in Phase 2 oral GLP-1 trial - Stock Titan
Structure Therapeutics Reports Positive Topline Data from Phase 2 ACCESS II Trial with Once-Daily Oral Small Molecule GLP-1 Receptor Agonist, Aleniglipron - Bitget
Why Structure Therapeutics Shares Are Sliding Today - TipRanks
HighVista Strategies LLC Acquires 149,615 Shares of Structure Therapeutics Inc. Sponsored ADR $GPCR - MarketBeat
First Light Asset Management LLC Boosts Holdings in Structure Therapeutics Inc. Sponsored ADR $GPCR - MarketBeat
ArrowMark Colorado Holdings LLC Boosts Stock Position in Structure Therapeutics Inc. Sponsored ADR $GPCR - MarketBeat
Structure Therapeutics Inc. Sponsored ADR $GPCR Shares Bought by Casdin Capital LLC - MarketBeat
Baker BROS. Advisors LP Sells 952,658 Shares of Structure Therapeutics Inc. Sponsored ADR $GPCR - MarketBeat
Analysts Offer Insights on Healthcare Companies: AbbVie (ABBV), Pliant Therapeutics (PLRX) and Opus Genetics (IRD) - The Globe and Mail
Assessing Structure Therapeutics (GPCR) Valuation After Its Quarterly Profit Turnaround - Sahm
Analysts Offer Insights on Healthcare Companies: Mineralys Therapeutics, Inc. (MLYS), Cartesian Therapeutics (RNAC) and Vertex Pharmaceuticals (VRTX) - The Globe and Mail
Why Structure Therapeutics (GPCR) Is Down 7.6% After Swinging to Q4 Profit and Filing a $236M Shelf RegistrationAnd What's Next - Sahm
Jefferies Financial Group Inc. Acquires New Holdings in Structure Therapeutics Inc. Sponsored ADR $GPCR - MarketBeat
Structure Therapeutics Inc. Sponsored ADR (NASDAQ:GPCR) Given Consensus Rating of "Moderate Buy" by Brokerages - MarketBeat
Structure Therapeutics inks major GLP-1 licensing deal - MSN
Rhenman & Partners Asset Management AB Purchases 45,000 Shares of Structure Therapeutics Inc. Sponsored ADR $GPCR - MarketBeat
Trading Systems Reacting to (GPCR) Volatility - Stock Traders Daily
Analysts Offer Insights on Healthcare Companies: BridgeBio Oncology Therapeutics (BBOT), Structure Therapeutics, Inc. Sponsored ADR (GPCR) and Ardent Health Partners, Inc. (ARDT) - The Globe and Mail
Analysts Offer Insights on Healthcare Companies: PepGen Inc. (PEPG) and Compass Therapeutics (CMPX) - The Globe and Mail
Tax withholding trims Structure Therapeutics (NASDAQ: GPCR) CMO stake - Stock Titan
Structure Therapeutics (GPCR) CSO has 18,735 shares withheld for taxes - Stock Titan
Structure Therapeutics (GPCR) CFO logs tax-withholding share disposition - Stock Titan
Structure Therapeutics (GPCR) CDO reports tax share and ESPP transactions - Stock Titan
Structure Therapeutics (GPCR) CEO reports tax share withholding and large trust-held stake - Stock Titan
HC Wainwright Issues Negative Estimate for GPCR Earnings - MarketBeat
Lilly Stock Down 5% in a Month: Should You Buy Now or Steer Clear? - TradingView
Structure Therapeutics Stock Surges 200% This Past Year as One Fund Cuts Stake by $15.5 Million - AOL.com
Finanzdaten der Structure Therapeutics Inc Adr-Aktie (GPCR)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.37%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):